Century Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPSC research report →
About the company
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy.
- CEO
- Brent Pfeiffenberger
- IPO
- 2021
- Employees
- 140
- HQ
- Philadelphia, PA, US
Price Chart
- Market Cap
- $210.36M
- P/E
- -1.94
- P/S
- 0.00
- P/B
- 0.79
- EV/EBITDA
- -2.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.23%
- ROIC
- -36.86%
- Revenue
- $109.16M · 1556.76%
- Net Income
- $-9,580,000 · 92.43%
- EPS
- $-0.11 · 93.17%
- Op Income
- $-15,040,000
- FCF YoY
- 5.05%
- 52W High
- $3.04
- 52W Low
- $0.43
- 50D MA
- $2.28
- 200D MA
- $1.60
- Beta
- 1.57
- Avg Volume
- 1.30M
Get TickerSpark's AI analysis on IPSC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 12, 26 | Russotti Gregory | sell | 2,584 |
| Jun 12, 26 | Carr Douglas | sell | 1,654 |
| Jun 11, 26 | Pfeiffenberger Brent | other | 13,849 |
| Jun 11, 26 | Cowan Chad | other | 358 |
| Jun 11, 26 | Riva Alessandro | other | 74,000 |
| Jun 11, 26 | Quimi Daphne | other | 74,000 |
| Jun 11, 26 | Murphy Martin Patrick | other | 74,000 |
| Jun 11, 26 | Lee Han Myung | other | 74,000 |
| Jun 11, 26 | Blackwell Kimberly | other | 74,000 |
| Jun 8, 26 | Russotti Gregory | sell | 524 |
Our IPSC coverage
Recent articles, reports, and earnings notes.
No research on IPSC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IPSC report →Similar companies
Peers in the same neighborhood.